Eosinophilic asthma (also known as e-asthma or eos asthma) is a severe form of asthma that causes high levels of eosinophils in the lung tissue, blood, and mucus. Eosinophils are a type of immune ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Targeted biologic drugs have revolutionized the treatment of severe asthma driven by eosinophils, which are white blood cells ...

A study reveals that shape-shifting immune cells, intermediate ILC2s, may contribute to severe asthma and resistance to ...

Specifically, Dupixent is approved to treat moderate to severe asthma that is either: dependent on treatment with an oral corticosteroid, or eosinophilic (caused by an increase in eosinophils ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and presents some key findings from recent patient research conducted in Europe ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Please provide your email address to receive an email when new articles are posted on . Twelve months prior to benralizumab treatment, 380 patients received at least one biologic. Patients without vs.

Targeted biologic drugs have revolutionized the treatment of severe asthma driven by eosinophils, which are white blood cells linked to ILC2s, researchers noted in a recent study in the journal ...